Home › Funds › Invesco › Invesco Pharmaceuticals ETF
Fund family: Invesco · Filed by INVESCO EXCHANGE-TRADED FUND TRUST (CIK 1209466) · SEC series S000003031
Ticker: PJP (C000008298)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 322 with, 13 against, 0 abstentions (not counted as with management). Shareholder proposals: 1 FOR, 12 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Invesco’s manager page (413,145 ballot items across 270 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Invesco | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 97.8% | 316 | 94.5% | 357,245 |
| Backed environmental and social shareholder proposals at US companies | n/a | 6 | 3.1% | 5,987 |
Each ballot item this fund voted is set against the votes of the other Invesco funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted the same way as most Invesco funds on all 306 items where a comparison was possible.
The same votes as “with management” above, by the sector of the company voted on. 97.3% of this fund’s 335 such votes could be given a sector; the other 9 (2.7%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 326 | 13 | 4.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 236 | 0 |
| Say-on-Pay | 35 | 0 |
| Audit-related | 30 | 0 |
| Compensation | 14 | 0 |
| Corporate Governance | 12 | 7 |
| Capital Structure | 3 | 0 |
| Environment or Climate | 3 | 3 |
| Other Social Issues | 3 | 3 |
| Extraordinary Transactions | 2 | 0 |
| Shareholder Rights and Defenses | 1 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Johnson & Johnson | April 23, 2026 | $28M | 15 | 1 |
| AbbVie Inc. | May 8, 2026 | $28M | 8 | 1 |
| Eli Lilly and Company | May 4, 2026 | $27M | 10 | 2 |
| Amgen Inc. | May 19, 2026 | $26M | 15 | 1 |
| Gilead Sciences, Inc. | April 30, 2026 | $24M | 15 | 3 |
| Pfizer Inc. | April 23, 2026 | $23M | 16 | 1 |
| Ligand Pharmaceuticals Incorporated | June 5, 2026 | $18M | 11 | 0 |
| Merck & Co., Inc. | May 26, 2026 | $18M | 18 | 3 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| April 23, 2026 | Johnson & Johnson | Independent Board Chair Shareholder proposal | Against | For |
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | For | Against |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | Against | For |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 23, 2026 | Pfizer Inc. | Adopt an Independent Chair Policy Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| May 5, 2026 | Bristol-Myers Squibb Company | Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposal | Against | For |
339 ballot items at 31 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Invesco Pharmaceuticals ETF (PJP) voted at 31 shareholder meetings of 30 companies, on 339 ballot items in all. Where management made a recommendation, the fund followed it on 96.1% of the items and voted against it 13 times. Its most frequent area of disagreement was corporate governance (7 of its votes against management). It voted on 13 shareholder proposals. It voted FOR the board's own proposals more often than Invesco's funds as a whole (97.8% against 94.5%). It voted the same way as most Invesco funds on every item where a comparison was possible.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Invesco’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.